Evidence map›Paper›PMID 34572677›Full record

ArticleAntibiotics (Basel, Switzerland)2021

Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics.

Ping Yang, Shigeru Fujimura, Yawei Du, Bei Zhang, Li Yang, Masato Kawamura, Zhenhua Zhang, Suodi Zhai

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ping YangDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0001-5466-8426
Shigeru FujimuraDivision of Clinical Infectious Diseases & Chemotherapy, Tohoku Medical and Pharmaceutical University, Sendai 981-8558, Japan.
Yawei DuDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Bei ZhangDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Li YangDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0002-8119-653X
Masato KawamuraDivision of Clinical Infectious Diseases & Chemotherapy, Tohoku Medical and Pharmaceutical University, Sendai 981-8558, Japan.
Zhenhua ZhangDepartment of Medical Affairs, Sumitomo Pharmaceuticals (Suzhou) Co. Ltd., Shanghai 200025, China.
Suodi ZhaiDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to provide comparative information of pharmaceutical properties, including particle morphology and distribution uniformity, solubility, presence of residual solvent and insoluble particles, and antimicrobial activities, between brand-name meropenem (Mepem

Indexed as

antimicrobial susceptibility patternsdissolution timemeropenemmorphology of particlesstability

Identifiers

PMID34572677
PMCPMC8469160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.